Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 4,770	$ 2,964
General and administrative	3,061	1,284
Total operating expenses	7,831	4,248
Loss from operations	(7,831)	(4,248)
Other income:
Interest income	29	16
Total other income	29	16
Net loss	(7,802)	(4,232)
Comprehensive loss	$ (7,802)	$ (4,232)
Net loss per share attributable to common stockholders—basic and diluted	$ (0.60)	$ (18.70)
Weighted-average common shares outstanding—basic and diluted	12,945,546	230,860